108 related articles for article (PubMed ID: 34313176)
21. Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia.
Genthon A; Dragoi D; Memoli M; Hirsch P; Favale F; Suner L; Chaquin M; Boncoeur P; Marjanovic Z; Bonnin A; Sestili S; Dulery R; Malard F; Brissot E; Banet A; van de Wyngaert Z; Vekhoff A; Delhommeau F; Mohty M; Legrand O
Br J Haematol; 2022 Aug; 198(4):780-784. PubMed ID: 35615877
[No Abstract] [Full Text] [Related]
22. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.
Montesinos P; Fathi AT; de Botton S; Stein EM; Zeidan AM; Zhu Y; Prebet T; Vigil CE; Bluemmert I; Yu X; DiNardo CD
Blood Adv; 2024 Mar; ():. PubMed ID: 38507688
[TBL] [Abstract][Full Text] [Related]
23. Enasidenib.
Krämer A; Bochtler T
Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
[TBL] [Abstract][Full Text] [Related]
24. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
[TBL] [Abstract][Full Text] [Related]
25. Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Golub D; Iyengar N; Dogra S; Wong T; Bready D; Tang K; Modrek AS; Placantonakis DG
Front Oncol; 2019; 9():417. PubMed ID: 31165048
[TBL] [Abstract][Full Text] [Related]
26. Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature.
Gasparovic L; Weiler S; Higi L; Burden AM
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081000
[TBL] [Abstract][Full Text] [Related]
27. Targeting mitochondrial metabolism in acute myeloid leukemia.
Rex MR; Williams R; Birsoy K; Ta Llman MS; Stahl M
Leuk Lymphoma; 2022 Mar; 63(3):530-537. PubMed ID: 34704521
[TBL] [Abstract][Full Text] [Related]
28. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications.
Lee S; Urman A; Desai P
Leuk Lymphoma; 2019 Nov; 60(11):2635-2645. PubMed ID: 30958073
[TBL] [Abstract][Full Text] [Related]
29. An evaluation of enasidenib for the treatment of acute myeloid leukemia.
Del Principe MI; Paterno G; Palmieri R; Maurillo L; Buccisano F; Venditti A
Expert Opin Pharmacother; 2019 Nov; 20(16):1935-1942. PubMed ID: 31454277
[No Abstract] [Full Text] [Related]
30. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
31. Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.
Lachowiez C; DiNardo CD; Stein E
Cancer J; 2022 Jan-Feb 01; 28(1):21-28. PubMed ID: 35072370
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic targeting of isocitrate dehydrogenase mutant AML.
Boddu P; Borthakur G
Expert Opin Investig Drugs; 2017 May; 26(5):525-530. PubMed ID: 28388242
[No Abstract] [Full Text] [Related]
33. Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
[TBL] [Abstract][Full Text] [Related]
34. Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML.
Khan M; Roddy JT; Hernandez JR; Bursch K; Bal N; Carlson KS; Bergl PA
Br J Haematol; 2021 Sep; 194(6):1083-1085. PubMed ID: 34101165
[No Abstract] [Full Text] [Related]
35. Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy.
Galkin M; Jonas BA
Core Evid; 2019; 14():3-17. PubMed ID: 31118877
[No Abstract] [Full Text] [Related]
36. Ivosidenib Deemed Safe, Effective in AML.
Cancer Discov; 2018 Aug; 8(8):OF1. PubMed ID: 29934313
[TBL] [Abstract][Full Text] [Related]
37. The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.
Chen J; Yang J; Cao P
Mini Rev Med Chem; 2016; 16(16):1344-1358. PubMed ID: 27292784
[TBL] [Abstract][Full Text] [Related]
38. Updates on DNA methylation modifiers in acute myeloid leukemia.
Contieri B; Duarte BKL; Lazarini M
Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
[TBL] [Abstract][Full Text] [Related]
39. Novel IDH1-Targeted Glioma Therapies.
Karpel-Massler G; Nguyen TTT; Shang E; Siegelin MD
CNS Drugs; 2019 Dec; 33(12):1155-1166. PubMed ID: 31768950
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of mutant IDH1 in acute myeloid leukaemia.
Yaqub F
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638561
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
